These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22612418)

  • 1. FT23, an orally active antifibrotic compound, attenuates structural and functional abnormalities in an experimental model of diabetic cardiomyopathy.
    Tan SM; Zhang Y; Wang B; Tan CY; Zammit SC; Williams SJ; Krum H; Kelly DJ
    Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):650-6. PubMed ID: 22612418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FT011, a new anti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy.
    Zhang Y; Edgley AJ; Cox AJ; Powell AK; Wang B; Kompa AR; Stapleton DI; Zammit SC; Williams SJ; Krum H; Gilbert RE; Kelly DJ
    Eur J Heart Fail; 2012 May; 14(5):549-62. PubMed ID: 22417655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction.
    Zhang Y; Elsik M; Edgley AJ; Cox AJ; Kompa AR; Wang B; Tan CY; Khong FL; Stapleton DI; Zammit S; Williams SJ; Gilbert RE; Krum H; Kelly DJ
    Int J Cardiol; 2013 Sep; 168(2):1174-85. PubMed ID: 23219315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta.
    Martin J; Kelly DJ; Mifsud SA; Zhang Y; Cox AJ; See F; Krum H; Wilkinson-Berka J; Gilbert RE
    Cardiovasc Res; 2005 Feb; 65(3):694-701. PubMed ID: 15664396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α11 integrin stimulates myofibroblast differentiation in diabetic cardiomyopathy.
    Talior-Volodarsky I; Connelly KA; Arora PD; Gullberg D; McCulloch CA
    Cardiovasc Res; 2012 Nov; 96(2):265-75. PubMed ID: 22869616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy.
    Mifsud S; Kelly DJ; Qi W; Zhang Y; Pollock CA; Wilkinson-Berka JL; Gilbert RE
    Nephron Physiol; 2003; 95(4):p83-91. PubMed ID: 14694265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transplantation of bone marrow-derived endothelial progenitor cells attenuates myocardial interstitial fibrosis and cardiac dysfunction in streptozotocin-induced diabetic rats.
    Cheng Y; Guo S; Liu G; Feng Y; Yan B; Yu J; Feng K; Li Z
    Int J Mol Med; 2012 Oct; 30(4):870-6. PubMed ID: 22859217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat.
    Connelly KA; Kelly DJ; Zhang Y; Prior DL; Martin J; Cox AJ; Thai K; Feneley MP; Tsoporis J; White KE; Krum H; Gilbert RE
    Cardiovasc Res; 2007 Nov; 76(2):280-91. PubMed ID: 17716638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor.
    Ihm SH; Chang K; Kim HY; Baek SH; Youn HJ; Seung KB; Kim JH
    Basic Res Cardiol; 2010 May; 105(3):399-407. PubMed ID: 19902320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy.
    Westermann D; Van Linthout S; Dhayat S; Dhayat N; Schmidt A; Noutsias M; Song XY; Spillmann F; Riad A; Schultheiss HP; Tschöpe C
    Basic Res Cardiol; 2007 Nov; 102(6):500-7. PubMed ID: 17909696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates.
    Zammit SC; Cox AJ; Gow RM; Zhang Y; Gilbert RE; Krum H; Kelly DJ; Williams SJ
    Bioorg Med Chem Lett; 2009 Dec; 19(24):7003-6. PubMed ID: 19879136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy.
    Kelly DJ; Zhang Y; Connelly K; Cox AJ; Martin J; Krum H; Gilbert RE
    Am J Physiol Heart Circ Physiol; 2007 Nov; 293(5):H2860-9. PubMed ID: 17720766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy.
    Van Linthout S; Seeland U; Riad A; Eckhardt O; Hohl M; Dhayat N; Richter U; Fischer JW; Böhm M; Pauschinger M; Schultheiss HP; Tschöpe C
    Basic Res Cardiol; 2008 Jul; 103(4):319-27. PubMed ID: 18347835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat.
    Gilbert RE; Zhang Y; Williams SJ; Zammit SC; Stapleton DI; Cox AJ; Krum H; Langham R; Kelly DJ
    PLoS One; 2012; 7(10):e47160. PubMed ID: 23071743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tranilast attenuates vascular hypertrophy, matrix accumulation and growth factor overexpression in experimental diabetes.
    Bonnet F; Cao Z; Cooper ME; Cox AJ; Kelly DJ; Gilbert RE
    Diabetes Metab; 2003 Sep; 29(4 Pt 1):386-92. PubMed ID: 14526266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac remodeling rather than disturbed myocardial energy metabolism is associated with cardiac dysfunction in diabetic rats.
    Bollano E; Omerovic E; Svensson H; Waagstein F; Fu M
    Int J Cardiol; 2007 Jan; 114(2):195-201. PubMed ID: 21882490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of tranilast on myocardial fibrosis in diabetes rats through TGF-β/Smad pathway.
    Li X; Liu J; Shang X
    Minerva Med; 2021 Feb; 112(1):153-154. PubMed ID: 31295986
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment with hydrogen molecule attenuates cardiac dysfunction in streptozotocin-induced diabetic mice.
    Wu F; Qiu Y; Ye G; Luo H; Jiang J; Yu F; Zhou W; Zhang S; Feng J
    Cardiovasc Pathol; 2015; 24(5):294-303. PubMed ID: 25979689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mechanism of reversion of myocardial interstitial fibrosis in diabetic cardiomyopathy by valsartan].
    Zhong M; Zhang Y; Miao Y; Li L; Gong HP; Ma X; Sun H; Zhang W
    Zhonghua Yi Xue Za Zhi; 2006 Jan; 86(4):232-6. PubMed ID: 16677501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3',4'-Bis-difluoromethoxycinnamoylanthranilate (FT061): an orally-active antifibrotic agent that reduces albuminuria in a rat model of progressive diabetic nephropathy.
    Williams SJ; Zammit SC; Cox AJ; Shackleford DM; Morizzi J; Zhang Y; Powell AK; Gilbert RE; Krum H; Kelly DJ
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6868-73. PubMed ID: 24169234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.